Aurinia Pharmaceuticals Inc. (AUP:TSX) Investor Relations Material

Overview

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company that is developing therapies for patients suffering from serious diseases with a high unmet medical need. Its main focus is on developing voclosporin, an investigational drug, for the treatment of lupus nephritis and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia, and has a commercial hub in Rockville, MD. Aurinia focuses its development efforts globally.

Frequently Asked Questions

What is Aurinia Pharmaceuticals Inc.'s ticker?

Aurinia Pharmaceuticals Inc.'s ticker is AUP

What exchange is Aurinia Pharmaceuticals Inc. traded on?

The company's shares trade on the TSX stock exchange

Where are Aurinia Pharmaceuticals Inc.'s headquarters?

They are based in Victoria, British Columbia

How many employees does Aurinia Pharmaceuticals Inc. have?

There are 201-500 employees working at Aurinia Pharmaceuticals Inc.

What is Aurinia Pharmaceuticals Inc.'s website?

It is https://www.auriniapharma.com/

What type of sector is Aurinia Pharmaceuticals Inc.?

Aurinia Pharmaceuticals Inc. is in the Healthcare sector

What type of industry is Aurinia Pharmaceuticals Inc.?

Aurinia Pharmaceuticals Inc. is in the Biotechnology industry

Who are Aurinia Pharmaceuticals Inc.'s peers and competitors?

The following five companies are Aurinia Pharmaceuticals Inc.'s industry peers:

- IVERIC bio

- Phathom Pharmaceuticals

- SpringWorks Therapeutics, Inc.

- Titan Pharmaceuticals Inc.

- Plus Therapeutics